Clean Sweep: Akerna Clients Win 100% of Iowa Medical Cannabis Dispensary Licenses – PRNewswire

DENVER, Oct. 8, 2020 /PRNewswire/ — Akerna (Nasdaq: KERN), an enterprise software, leading compliance technology provider, and developer of the cannabis industry’s first seed-to-sale enterprise resource planning (ERP) software technology (MJ Platform®), is thrilled to announce that two of its MJ Freeway consulting clients have been awarded the only two medical cannabis dispensary licenses in the state of Iowa.

The license winners were:

  • Iowa Cannabis Company East
  • Cannabis Patient Network

MJ Freeway’s cannabis consulting team has 30+ years of combined experience in the cannabis industry. The team has completed applications in 17 different states and have won very competitive licenses in states like Arkansas, Ohio, Pennsylvania, Missouri, and most recently Iowa.

With Arizona, Montana, Mississippi, New Jersey, Oregon, and South Dakota all having legalization measures on the ballot for this upcoming election in November, Akerna remains poised to assist clients in capitalizing on the opportunities these emerging states present.

„We are thrilled and humbled to have helped Iowa Cannabis Company East and Canna3bis Patient Network in winning their medical cannabis dispensary licenses,” said Matthew Lawson-Baker, Director of Consulting, MJ Freeway. „Iowa is an incredibly competitive market, and the fact that our clients swept the state is a testament both to them and our incredibly talented and experienced consulting team.”

About Akerna:
Akerna is a global regulatory compliance technology company. Akerna’s service offerings include MJ Platform®, Leaf Data Systems®, solo sciences tech platform and Ample Organics. Since its establishment in 2010, Akerna has tracked more than $18 billion in cannabis sales. Akerna is based in Denver. For more information, please visit and follow us on Twitter @AkernaCorp.

Forward-Looking Statements

Certain statements made in this release are „forward-looking statements” within the meaning of the „safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words „estimates,” „projected,” „expects,” „anticipates,” „forecasts,” „plans,” „intends,” „believes,” „seeks,” „may,” „will,” „should,” „future,” „propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. Such forward-looking statements include but are not limited to statements regarding the ability of MJ Freeway consulting team to assist clients in capitalizing on the opportunities in new markets in the cannabis space. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of significant known and unknown risks, uncertainties, assumptions, and other important factors, many of which are outside Akerna’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others that may affect actual results or outcomes, include (i) Akerna’s ability to maintain relationships with customers and suppliers and retain its management and key employees, (ii) changes in applicable laws or regulations, (iii) changes in the market place due to the coronavirus pandemic or other market factors, (iv) and other risks and uncertainties disclosed from time to time in Akerna’s filings with the U.S. Securities and Exchange Commission, including those under „Risk Factors” therein.  You are cautioned not to place undue reliance on forward-looking statements. All information herein speaks only as of the date hereof, in the case of information about Akerna, or the date of such information, in the case of information from persons other than Akerna. Akerna undertakes no duty to update or revise the information contained herein. Forecasts and estimates regarding Akerna’s industry and end markets are based on sources believed to be reliable; however, there can be no assurance these forecasts and estimates will prove accurate in whole or in part.


Related Links

Dodaj komentarz